Bimatoprost/Brimonidine Tartrate/Timolol

贝美前列素/酒石酸溴莫尼定/噻吗洛尔

Report date: 2023/09/15 15:14:18

Base Information

Drug NameBimatoprost/Brimonidine Tartrate/Timolol
Drug Alias NameTimolol/brimonidine/bimatoprostBimatoprost/Brimonidine/TimololBimatoprost/timolol/brimonidine
ClassificationSmall molecules
Mechanisms of ActionBeta adrenergic receptors antagonistsAdrenergic receptors alpha-2 agonistsProstanoid receptor agonists
TargetsBeta adrenergic receptorsProstanoid receptorAdrenergic receptors alpha-2
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMexicoColombiaIndia
CombinationsYes BimatoprostBrimonidine TartrateTimolol
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllergan Plc
Active IndicationsN/A
Inactive IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension

Other Information

ATC CodeN/A
Related LinksN/A